BioCryst Pharmaceuticals, Inc. announced that Health Canada has approved RAPIVAB® (peramivir injection), an intravenous (I.V.) treatment for acute, uncomplicated influenza.  RAPIVAB is approved by the U.S. Food & Drug Administration (FDA) and is also licensed for use in Japan and Taiwan as RAPIACTA® and in Korea as PeramiFlu®.